Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE.
Head-to-head clinical analysis: LABETALOL HYDROCHLORIDE IN DEXTROSE versus METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE.
LABETALOL HYDROCHLORIDE IN DEXTROSE vs METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
Metoprolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume and blood pressure.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
Oral: 50-100 mg metoprolol tartrate/12.5-25 mg hydrochlorothiazide once or twice daily; maximum 200 mg metoprolol/50 mg hydrochlorothiazide per day.
None Documented
None Documented
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Metoprolol: 3–7 h (terminal), clinical context: may require twice-daily dosing; prolonged in hepatic impairment. Hydrochlorothiazide: 6–15 h (terminal), clinical context: supports once-daily dosing; prolonged in renal impairment.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Metoprolol: <5% renal (unchanged), >95% hepatic metabolism, metabolites excreted renally. Hydrochlorothiazide: >95% renal (unchanged).
Category A/B
Category C
Alpha/Beta-Blocker
Beta-Blocker